Puma Biotechnology (PBYI) Assets Average (2011 - 2026)

Puma Biotechnology's Assets Average history runs 16 years deep, the most recent figure standing at $204.5 million for Q1 2026.

• Quarterly Assets Average changed 0.13% year-over-year to $204.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.5 million (changed 0.13% YoY) and the FY2025 annual result came in at $214.8 million, down 3.21% from the prior year.
• Assets Average was $204.5 million for Q1 2026 at Puma Biotechnology, down from $209.6 million in the prior quarter.
• Across five years, Assets Average topped out at $222.3 million in Q1 2024 and bottomed at $195.5 million in Q2 2025.
• A 5-year average of $207.0 million and a median of $209.2 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average fell 23.97% — and 2024, when it increased 6.3%.
• Puma Biotechnology's Assets Average stood at $210.4 million in 2022, then gained by 3.16% to $217.1 million in 2023, then slipped by 0.02% to $217.0 million in 2024, then fell by 3.43% to $209.6 million in 2025, then decreased by 2.42% to $204.5 million in 2026.
• Business Quant data shows PBYI's Assets Average at $204.5 million in Q1 2026, $209.6 million in Q4 2025, and $198.9 million in Q3 2025.